Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse

NCT05706038 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.

NCT NCT05706038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05706038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse
Lead sponsor
IRCCS San Raffaele
Phase
Observational
Overall status
Completed
Start date
April 27, 2022
Completion date
October 31, 2022
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel diseases, rheumatic disorder